ALK and non-small cell lung carcinoma: In 2021, Camidge et al. reported the benefits of brigatinib as first-line therapy in patients with ALK inhibitor naïve -ALK-positive NSCLC, with superior 3-year PFS versus crizotinib, and increased survival in those with brain metastases148.